PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles

Subjects will receive up to 4 study treatments with the PicoWay™ 730 nm laser wavelength,
PicoWay™1064nm fractional handpiece and/or PicoWay™ 1064nm fractional handpiece for treatment
of benign pigmented lesions or wrinkles. Subjects will return for three follow-up visit
evaluations 1-month, 2-months and 3-months post final study treatment. Primary efficacy
assessed by masked photographic evaluation. Optional biopsy collection for histological
analysis of laser tissue effects.

Inclusion Criteria

1. Willing to provide signed informed consent

2. Adults age 21 to 80

3. Fitzpatrick Skin Type (FST) I to VI

4. Presence of benign pigmented Lesions assessed at baseline as Pigment Severity Score
(PSS) of "2" or higher and/or wrinkles assessed at baseline as Fitzpatrick Wrinkle
Score (FWS) of "2" or higher

5. Willing to allow photographs and/or video to be taken of treated areas for the
purposes of this research study

6. Willing to abstain from any other procedures for treatment of benign pigmented lesions
or wrinkles in the laser treatment areas for the duration of the study including
surgery, light, laser, ultrasound or radiofrequency treatments

7. Willing to abstain from use of prescription cosmetic products for treatment of benign
pigmented lesions or wrinkles in the laser treatment areas for the duration of the
study including injections of neurotoxins or dermal fillers, skin lightening creams,
and wrinkle creams

8. Willingness to adhere to study treatment and follow-up visit schedules

Exclusion Criteria

1. Pregnant, planning pregnancy or breast feeding

2. Allergy to topical or injectable lidocaine or similar medications

3. Allergy to topical steroid or similar medications

4. Unprotected sun exposure in the six weeks prior to enrollment, or active tan in the
laser treatment area

5. History of melanoma in the intended treatment area

6. History of keloid or hypertrophic scar formation

7. Use of topical or systemic retinoid therapy during the past six (6) months

8. Use of neurotoxins in the intended treatment area within the past three (3) months or
throughout the duration of the study

9. Use of dermal fillers in the intended treatment area within the last six (6) months or
throughout the duration of the study

10. Severe immunosuppression resulting from medications and/or a medical condition that
could impair healing after treatment.

11. Open wound or infection in the intended treatment area

12. History of light induced seizure disorders

13. Dermatologic and/or cosmetic procedures in the intended treatment area(s) during the
past six months

14. The subject is not suitable, in the opinion of the clinician, for participation in the
study due to medical or other reasons that could compromise the study integrity or
subject safety